GILD
What one share of Gilead Sciences holds
Biological Products, (No Diagnostic Substances)
Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
Gilead Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $24.40 |
|---|---|
| Profit | −$2.60 |
| Capex (buildings and equipment) | $0.49 |
| Free cash flow | $10.37 |
| Dividends | $3.22 |
| Cash and investments | $2.56 |
| Debt | $21.15 |
| Book value | $9.53 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2007 | $2.19 | $0.82 | $0.04 | $0.82 | — | $2.02 |
| 2008 | $2.78 | $1.03 | $0.06 | $1.06 | — | $2.35 |
| 2009 | $3.75 | $1.41 | $0.12 | $1.53 | — | $3.54 |
| 2010 | $4.55 | $1.66 | $0.04 | $1.59 | — | $3.66 |
| 2011 | $5.31 | $1.77 | $0.08 | $2.22 | — | $4.47 |
| 2012 | $6.13 | $1.64 | $0.25 | $1.77 | — | $6.12 |
| 2013 | $6.61 | $1.81 | $0.08 | $1.75 | $0.00 | $7.41 |
| 2014 | $15.11 | $7.35 | $0.34 | $7.44 | $0.00 | $10.29 |
| 2015 | $21.46 | $11.91 | $0.49 | $13.48 | $1.29 | $13.03 |
| 2016 | $22.38 | $9.94 | $0.55 | $12.00 | $1.84 | $14.42 |
| 2017 | $19.79 | $3.51 | $0.45 | $8.57 | $2.08 | $15.63 |
| 2018 | $16.92 | $4.17 | $0.71 | $5.72 | $2.28 | $16.68 |
| 2019 | $17.58 | $4.22 | $0.65 | $6.51 | $2.52 | $17.79 |
| 2020 | $19.55 | $0.10 | $0.51 | $5.95 | $2.72 | $14.52 |
| 2021 | $21.64 | $4.93 | $0.46 | $8.56 | $2.84 | $16.80 |
| 2022 | $21.62 | $3.64 | $0.58 | $6.61 | $2.92 | $17.03 |
| 2023 | $21.55 | $4.50 | $0.47 | $5.90 | $3.00 | $18.32 |
| 2024 | $22.91 | $0.38 | $0.42 | $8.21 | $3.08 | $15.51 |
| 2025 | $23.46 | $6.78 | $0.45 | $7.53 | $3.16 | $18.29 |